Skip to main content


Virtual Independent Supported Sessions 

Tune in throughout the year for the Virtual Independent Supported Sessions. The sessions are independently-sponsored and will offer various educational topics in the field of neuro-oncology. The sessions will be broadcasted live and recorded for on-demand viewing. 

Current Webinars

Laser Ablation in Neuro-Oncology

Presented and Supported by Monteris Medical.  

The program includes a comprehensive review of clinical evidence supporting the use of laser ablation for glioblastoma, brain metastases, and radiation necrosis. The distinguished speakers will also share experiences from their institutions and take questions from the audience. The intended audience is Medical Oncologists, Neuro-Oncologists, and Radiation Oncologists.  The faculty is John de Groot, MD (University of Texas MD Anderson Cancer Center, Houston, TX0 and Roy Strowd III, MEd, MD, MS (Wake Forest Baptist Health, Winston-Salem, NC).  

To view the session, click here.

A Multidisciplinary Approach to Treating Glioblastoma  

Presented and Supported by Novocure.  

This session is a multidisciplinary panel of experts in a tumor-board style forum.  The panel discusses and give the attendees insights on the care and management of a diverse patient population with difficult-to-treat solid malignancies, such as glioblastoma (GBM). Panelists include Dr. Priya Kumthekar (Neuro-Oncologist; Northwestern University), Dr. Jennifer Moliterno( Neurosurgeon; Yale University), Dr. Norleena Gullett (Radiation Oncologist; Duke University) and Jennifer Serventi (Physician Assistant, University of Rochester). 

To view the session, click here.

Neuro-Oncology Perspectives in Neurofibromatosis Type 1: New Horizons in the Era of MEK Inhibition

Presented by Creative Educational Concepts, Inc (CEC Oncology).
Supported by an independent educational grant from AstraZeneca.

This educational initiative is targeted to neuro-oncologists, pediatric neuro-oncologists, neurosurgeons, neuroradiologists, medical oncologists, neurologists, neuro-oncology researchers, and other members of the neuro-oncology team who care for patients with neurofibromatosis type 1 (NF1). Designed and developed to provide an exhaustive overview of novel and emerging data, as well as establish a foundational context of NF1 disease state complexity, this activity will begin by identifying keystone diagnostic signs, symptoms, and clinical hallmarks in pediatric patients, and describe the genetic etiologies and multi-system pathophysiologies that have historically made NF1-associated plexiform neurofibromas so difficult to treat. Attendees will then gain insights from expert faculty regarding the pivotal shortcomings of traditional treatment approaches and the new horizons that have accompanied the burgeoning emergence of novel pharmacologic therapies, most notably MEK inhibitors. Finally, top-level clinical experts will guide attendees through a case-based section that explores the vital role of the neuro-oncology clinician and researcher in the evolving NF1 management paradigm, and provides activity participants an opportunity to design evidence-based treatment regimens for symptomatic, inoperable NF1-related tumors
View Webinar and Receive CME Credit